Business Information
The group's principal activities are to discover and develop pharmaceutical products for neurologic and endocrine diseases and disorders. The group has developed therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes. The product candidates in clinical development include indiplon for insomnia, gnrh antagonist for endometriosis, altered peptide ligand for multiple sclerosis and diabetes, d2 receptor agonist for sexual dysfunction, crf r1 antagonist for anxiety and depression, crf r2 peptide agonist for cardiovascular system and il-4 fusion toxin for tumors and malignant glioma. The group currently has 13 programs in various stages of research and development, including clinical development. It currently has active product development collaborations with pfizer, inc., glaxosmithkline , wyeth and taisho pharmaceutical co., ltd.
|
|
Name |
Title
|
Email
|
| Joseph Mollica | Chmn. | N/A | | Kevin Gorman | Dir., CEO, Pres. | N/A | | Christopher O'Brien | Chief Medical Officer | N/A | | Tim Coughlin | CFO, VP | N/A | | Barbara Finn | VP - Regulatory Affairs - Quality Assurance | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 39,234 | (107,205) | | 2005 | 123,889 | (22,191) | | 2004 | 85,176 | (45,773)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
